The Journal of clinical endocrinology and metabolism · 2026
Early pregnancy biomarkers of inflammation and metabolic regulation in polycystic ovary syndrome.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alesi Simon, Mason Taitum, Ellery Stacey J, Rassie Kate, Neven Adriana C H, Belsti Yitayeh, Jona Eveline, O'Reilly Sharleen, Simmons David, Teede Helena, Mousa Aya, IMPACT DIABETES B2B&ME, TOBOGM Study Groups
Аннотация
OBJECTIVE: To profile biomarkers of inflammation and metabolic regulation in early pregnancy among women with and without polycystic ovary syndrome (PCOS), and to assess whether these biomarkers influence the relationship between PCOS and adverse maternal or neonatal outcomes.
DESIGN: Cross-sectional study with interaction analyses using pooled baseline data from 2 international multicenter clinical trials.
SUBJECTS: One hundred and fifty-one pregnant women (at <24 weeks' gestation) at risk of gestational diabetes mellitus, including 65 with PCOS and 86 without PCOS.
MAIN OUTCOME MEASURES: Early pregnancy markers of inflammation and metabolic regulation were assessed, including C-reactive protein, tumor necrosis factor-α, interleukins, monocyte chemoattractant protein-1 (MCP1), fatty acid binding protein-4 (FABP4), growth differentiation factor-15, and adipokines (total adiponectin, leptin, resistin, chemerin, vaspin, and cathepsin-S). Biomarkers differing by PCOS status were further examined for interaction effects on maternal and neonatal outcomes.
RESULTS: Monocyte chemoattractant protein-1 concentrations were 15% higher in women with PCOS compared with those without (geometric mean ratio [GMR]: 1.15; 95% CI: 1.01, 1.31; P & .04), but this association was attenuated after adjustment for maternal age and body mass index (BMI). Early pregnancy FABP4 concentrations were 32% higher in women with PCOS compared with those without (GMR: 1.32; 95% CI: 1.04, 1.68; P & .02), and this association remained significant after adjustment for maternal age (GMR: 1.34; 95% CI: 1.05-1.71; P & .02), but was attenuated after adjustment for BMI. No other biomarkers differed by PCOS status, and MCP1 or FABP4 showed no interactions with maternal or neonatal outcomes.
CONCLUSION: Monocyte chemoattractant protein-1 and FABP4 concentrations were elevated in early pregnancy among women with PCOS, largely reflecting maternal adiposity. These markers did not modify associations between PCOS and pregnancy outcomes. Larger longitudinal studies are needed to clarify underlying inflammatory and metabolic pathways.
DESIGN: Cross-sectional study with interaction analyses using pooled baseline data from 2 international multicenter clinical trials.
SUBJECTS: One hundred and fifty-one pregnant women (at <24 weeks' gestation) at risk of gestational diabetes mellitus, including 65 with PCOS and 86 without PCOS.
MAIN OUTCOME MEASURES: Early pregnancy markers of inflammation and metabolic regulation were assessed, including C-reactive protein, tumor necrosis factor-α, interleukins, monocyte chemoattractant protein-1 (MCP1), fatty acid binding protein-4 (FABP4), growth differentiation factor-15, and adipokines (total adiponectin, leptin, resistin, chemerin, vaspin, and cathepsin-S). Biomarkers differing by PCOS status were further examined for interaction effects on maternal and neonatal outcomes.
RESULTS: Monocyte chemoattractant protein-1 concentrations were 15% higher in women with PCOS compared with those without (geometric mean ratio [GMR]: 1.15; 95% CI: 1.01, 1.31; P & .04), but this association was attenuated after adjustment for maternal age and body mass index (BMI). Early pregnancy FABP4 concentrations were 32% higher in women with PCOS compared with those without (GMR: 1.32; 95% CI: 1.04, 1.68; P & .02), and this association remained significant after adjustment for maternal age (GMR: 1.34; 95% CI: 1.05-1.71; P & .02), but was attenuated after adjustment for BMI. No other biomarkers differed by PCOS status, and MCP1 or FABP4 showed no interactions with maternal or neonatal outcomes.
CONCLUSION: Monocyte chemoattractant protein-1 and FABP4 concentrations were elevated in early pregnancy among women with PCOS, largely reflecting maternal adiposity. These markers did not modify associations between PCOS and pregnancy outcomes. Larger longitudinal studies are needed to clarify underlying inflammatory and metabolic pathways.